F2G and Shionogi announce positive topline results from global Phase 3 OASIS study evaluating oral olorofim versus AmBisome® followed by Standard of Care in patients with invasive aspergillosis
SOMAREALITY secures over €3 million in an oversubscribed Series A round led by Catalyst Romania to become the world’s first full cognitive insights solution based solely on eye tracking